Granisetron Injection is indicated for: The prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, therapy including high dose cisplatin. The prevention and treatment of postoperative nausea and vomiting.
Granisetron Tablet is indicated for: Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high dose of cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.
Granisetron is contraindicated in patients with known hypersensitivity to Granisetron or any of its components.
Headache, constipation, asthenia, diarrhea, abdominal pain, dyspepsia, nausea and vomiting, dizziness, insomnia, and anxiety.
Pregnancy category B. No evidence of impaired fertility or harm to the animal fetus has been found. However, this drug may be used in pregnancy only if clearly needed. It is not known whether Granisetron is excreted in human milk. So caution should be exercised when granisetron is administered to a nursing mother.
Patient with cardiac co-morbidities, on cardiotoxic chemotherapy and/or woth concomitant electrolyte abnormalities. May mask progressive ileus and/or gastric distention. Childn. Pregnancy and lactation.
Pediatric Uses: The safety and effectiveness of granisetron in pediatric patients under 2 years have not been established.
Geriatric use: Efficacy and safety were maintained with increasing age.
Anti-emetic drugs, Supportive Care Therapy
lnjection: Store below 25°C.Protect from light. Tablet: Store below °C.Protect from light.
